Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of SGN-LIV1A in Patients With Metastatic Breast Cancer

NCT01969643 is registered in ClinicalTrials.gov with Seagen Inc. as lead sponsor.

NCT NCT01969643
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01969643 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of SGN-LIV1A in Patients With Metastatic Breast Cancer
Lead sponsor
Seagen Inc.
Phase
Phase 1
Overall status
Completed
Start date
October 22, 2013
Completion date
February 4, 2023
Enrollment
290 (actual)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

her2 mutations breast neoplasms, her2 positive breast neoplasms, hormone receptor positive breast neoplasms, triple negative breast neoplasms